Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bionano Genomics, Inc. (NASDAQ: BNGO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer, Bionano submits annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that describe its financial condition, results of operations, risk factors and material corporate events.
Bionano’s recent Forms 8-K include disclosures about quarterly financial results, such as reports for the second and third quarters of 2025, and about capital markets transactions, including a September 2025 public offering of common stock and Series E and Series F warrants. The company has also filed a registration statement on Form S-1 relating to offerings of common stock, pre-funded warrants and warrants, which outlines offering terms, risk factors and use of proceeds.
Through this page, users can review Bionano’s descriptions of its business as a provider of optical genome mapping (OGM) solutions, diagnostic services and software, as well as its discussion of revenue sources, cost structure and liquidity. Filings may also include information on shareholder votes, such as the corrected voting results reported in an 8-K/A filed in June 2025, and details of securities purchase agreements and engagement letters with placement agents for public offerings.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify topics such as OGM adoption, consumables and software utilization, capital raises and going concern considerations. Investors can use this resource to track Bionano’s Forms 10-K and 10-Q for comprehensive financial statements, Forms 8-K for event-driven updates, and registration statements for securities offerings, while AI-generated insights assist in understanding the implications of each filing.
CVI Investments, Inc. and Heights Capital Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 1,129,411 shares of Bionano Genomics, Inc. common stock, representing 9.9% of the class.
The reported position consists of shares issuable upon exercise of warrants, which are subject to 4.99% and 9.99% beneficial ownership limits that restrict further exercises above those thresholds. Bionano had 10,176,000 shares outstanding as of November 5, 2025. The reporting parties certify the holdings were not acquired to change or influence control of the company.
Bionano Genomics, Inc. reported an insider equity award to its Principal Accounting Officer, Mark Adamchak. On February 2, 2026, he received a stock option giving him the right to buy 10,890 shares of common stock at an exercise price of $1.27 per share. The option was granted at no cost and is held directly. According to the filing, 100% of the shares subject to the option vest on the one-year anniversary of the grant date, aligning his compensation more closely with the company’s future share performance.
Bionano Genomics reported an insider equity award for its Chief Medical Officer, Alka Chaubey. On 02/02/2026, Chaubey received a stock option to buy 27,737 shares of common stock at an exercise price of $1.27 per share. The option vests monthly over 48 months, beginning on the one-month anniversary of the vesting commencement date, and becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, Chaubey beneficially owns 27,737 derivative securities directly, and the filing does not report any share sales.
Bionano Genomics chief operating officer Mark Oldakowski received a grant of 27,737 stock options on February 2, 2026. The options give him the right to buy Bionano Genomics common stock at an exercise price of $1.27 per share and expire on February 1, 2036.
The award vests in monthly installments over 48 months, starting one month after the vesting commencement date, so the option becomes fully vested and exercisable on the four-year anniversary of that commencement date. Following this grant, he beneficially owns 27,737 derivative securities directly.
Bionano Genomics, Inc. reported a new equity award for its General Counsel, Jonathan V. Dixon. On 02/02/2026, he received a stock option to buy 26,117 shares of common stock at an exercise price of $1.27 per share. The option vests monthly over 48 months beginning on the one-month anniversary of the vesting commencement date, so it becomes fully vested and exercisable on the four-year anniversary of that date.
Bionano Genomics, Inc. reported that President and CEO, and director, Erik R. Holmlin received a grant of stock options on 02/02/2026. The award covers 69,484 options to buy common stock at an exercise price of $1.27 per share, expiring on 02/01/2036.
The options were awarded at a cost of $0 for the derivative itself and are held directly. They vest monthly over 48 months beginning one month after the vesting commencement date, so the option becomes fully vested and exercisable on the four-year anniversary of that date.
Bionano Genomics, Inc. filed a current report to disclose that it issued a press release with preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2025. The press release is provided as Exhibit 99.1, giving an early look at the company’s performance for that period. The report specifies that this preliminary financial information is being furnished, not filed, which limits its use for certain legal purposes. The document is signed on behalf of Bionano Genomics by President and Chief Executive Officer R. Erik Holmlin, Ph.D.
Bionano Genomics reported third‑quarter results showing higher revenue and a sharply narrower loss. Q3 2025 revenue was $7.367 million (vs. $6.073 million a year ago), driven by consumables and software, while net loss was $8.503 million (vs. $44.246 million). Cost of revenue fell significantly year over year, and operating expenses dropped without the prior year’s impairment and restructuring charges.
Liquidity remains tight. As of September 30, 2025, the company had $3.065 million in cash and cash equivalents, $18.516 million in investments, and $10.266 million in restricted short‑term investments. Management states there is “substantial doubt” about the company’s ability to continue as a going concern within 12 months without additional financing.
Convertible debentures outstanding totaled $10.266 million in principal, with monthly holder redemptions permitted and a conversion price of $16.20 per share subject to a beneficial ownership cap. Shares outstanding were 9,730,400 at quarter‑end and 10,176,000 as of November 5, 2025.
Bionano Genomics filed a Form 8-K stating it issued a press release reporting financial results for the third quarter ended September 30, 2025. The release is furnished under Item 2.02 and attached as Exhibit 99.1. In accordance with General Instruction B.2., the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically referenced.
BNGO updated its at-the-market program to permit sales of common stock of up to $9,924,517 through H.C. Wainwright under a Sales Agreement, subject to General Instruction I.B.6 limits.
For I.B.6 purposes, public float was $47,861,922, based on 9,728,033 non‑affiliate shares on October 9, 2025 and a $4.92 price on September 10, 2025. In the prior 12 months, the company sold $6,029,456 of securities under I.B.6; the new capacity excludes those sales. Wainwright will act as sales agent and receive a 3.0% commission on gross proceeds. The shares trade on Nasdaq as BNGO; the closing price was $1.99 on October 16, 2025.